texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Roger M. Lyons, M.D., FACP

General Summary

Dr. Roger M. Lyons is board certified in hematology and internal medicine. Dr. Lyons is actively involved in clinical research. His special interests in oncology are in hematologic malignancies, such as myelodysplasia, leukemia, lymphoma, and multiple myeloma. He is also interested in non-malignant hematological disorders such as thrombosis, coagulation, platelet, and vascular disorders. He has published over 42 articles and 72 abstracts in peer-reviewed journals, and has taken a leading role in over 40 research studies.

Education

  • Fellowship
    Washington University School of Medicine, St. Louis, MO
  • Residency
    Medicine, Winnipeg General Hospital; Medicine, Barnes and Wohl Hospitals, St. Louis, MO
  • Internship
    Winnipeg General Hospital, Winnipeg, Canada
  • Medical Doctorate
    University of Manitoba, Winnipeg, Canada

Medical Practice

Other Information

Accolades & Memberships

Dr. Lyons has received the special honor of being listed repeatedly in the Best Doctors in America.

Community Service

Research Interest

Publications

  • Relation Between Chelation and Clinical Outcomes in Lower-Risk Patients with Myelodysplastic Syndromes

    Leukemia Research, 2017

  • A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 hour, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma

    American Journal of Hematology , 2017

  • Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia.

    Haematologica, 2017

  • Iron Overload, Chelation Therapy and Survival in Lower-risk Myelodysplastic Syndromes: State of Evidence

    International Blood Research & Reviews, 2014

  • Comparison of 24-Month Outcomes in Chelated and non-Chelated Lower-risk Patients with Myelodysplastic Syndromes in a Prospective Registry

    Leukemia Research, 2014

Show all Publications
  • Interim Analysis of Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Count

    Journal of Hematology & Oncology, 2013

  • Comparison of Placebo and Best Available Therapy for the Treatment of Myelofibrosis in the Phase 3 COMFORT Studies

    Haematologica, 2013

  • Efficacy, Safety and Survival with Ruxolitinib Treatment in Patients with Myelofibrosis: Results of a Median 2-year Follow-up of COMFORT-1

    Haematologica, 2013

  • Self-Administration of Romiplostim in Patients with Chronic Immune Thrombocytopenia (ITP)

    Community Oncology, 2013

  • The Clinical Benefit of Ruxolitinib Across Patient Subgroups: Analysis of a Placebo-controlled, Phase III Study in Patients with Myelofibrosis

    British Journal of Haematology, 2013

  • Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenia (ITP): Safety and Efficacy

    British Journal of Haematology, 2013

  • Edoxaban for Long-Term Treatment of Venous Thromboembolism in Cancer Patients 

    55th American Society of Hematology Annual Meeting and Exposition, 2013

  • Long-Term Outcomes of Ruxolitinib Therapy in Patients with Myelofibrosis: 3-Year Update From COMFORT-1

    55th American Society of Hematology Annual Meeting and Exposition, 2013

  • The VIP (Very Immunocompromised Patient ) Protocol: Improved Access to Care and Time to Antibiotics

    55th American Society of Hematology Annual Meeting and Exposition, 2013

  • Interim Analysis of Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts

    Journal of Hematology & Oncology, 2013

  • Randomized, Placebo-Controlled, Phase I/II Trial of the Thrombopoietin Receptor (TPO-R) Agonist Eltrombopag in Thrombocytopenic Patients with Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia—A Subgroup Analysis of Patients Receiving Concomitant Anticancer Therapy

    55th American Society of Hematology Annual Meeting and Exposition, 2013

  • 48-Month Update on Survival and AML Transformation in a 600-Patient Registry of Lower-Risk MDS Patients

    55th American Society of Hematology Annual Meeting and Exposition, 2013

  • Placebo-controlled, Randomized, Phase I/II Trial of the Thrombopoeitin Receptor Agonist Eltrombopag in Thrombocytopenic Patients with Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia

    18th Congress of the European Hematology Association, 2013

  • A 36-Month Analysis of Treatment Patterns of Outcomes in Patients with Lower-Risk Myelodysplastic Syndromes from a Prospective Observational Study

    Journal of Clinical Oncology, 2013

  • Relationship Between Chelation and Clinical Outcomes in 600 Lower-Risk MDS Patients: Registry Analysis At 36 Months

    54th Annual Meeting of the American Society of Hematology, 2012

  • Oral Ezatiostat HCL (Telintra), a Glutathione Analog Prodrug GSTP-1Inhibitor, for Treatment of Patients with Myeloid Growth Factor-Resistant Idiopathic Chronic Neutropenia

    54th Annual Meeting of the American Society of Hematology, 2012

  • Integrated Analysis of Long-Term Safety in Patients with Chronic Immune Thrombocytopenia Treated with Romiplostim

    54th Annual Meeting of the American Society of Hematology, 2012

  • Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-1

    54th Annual Meeting of the American Society of Hematology, 2012

  • Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50-100 x 10^9/L): A Comparison to Patients with Normal or High Starting Platelet Counts

    54th Annual Meeting of the American Society of Hematology, 2012

  • Consistent Benefit of Ruxolitinib Over Placebo Across Myelofibrosis Patient Subgroups: Results From COMFORT-1

    European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, 2012

  • Preliminary Safety and Efficacy of Ruxolitinib in Patients with Primary and Secondary Myelofibrosis with Platelet Counts of 50-100x10^9L

    Journal of Clinical Oncology, 2012

  • Adverse Events and the Return of Myelofibrosis-Related Symptoms After Treatment Interruption or Discontinuation in the Comfort-I Study

    Journal of Clinical Oncology, 2012

  • Myelodysplastic Syndromes: Therapy and Outlook

    American Journal of Medicine, 2012

  • Phase 1 Dose-ranging Study of Ezatiostat Hydrochloride in Combination with Lenalidomide in Patients with Non-deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

    Journal of Hematology & Oncology, 2012

  • A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

    New England Journal of Medicine, 2012

  • A Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome Receiving Lenalidomide

    Journal of Hematology & Oncology, 2012

  • Oral Ezatiostat HCl (Telintra, TLK199) and Idiopathic Chronic Neutropenia (ICN): A Case Report of Complete Response of a Patient with G-CSF Resistant ICN Following Treatment with Ezatiostat, a Glutathionie S-transferase P1-1 (GSTP1-1) Inhibitor

    Journal of Hematology & Oncology, 2011

  • Outpatient Consolidation Treatment with Clofarabine in a Phase 2 Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia (AML)

    Leukemia and Lymphoma, 2011

  • A Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia

    Investigational New Drugs, 2011

  • Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-1)

    Blood, 2011

  • Phase I Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra, TLK199) in Combination with Lenalidomide (Revlimid) in Patients with Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

    Blood, 2011

  • Update of an Open-Label Extension Study Evaluating the Long-Term Safety & Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS)

    Blood, 2011

  • Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-1

    Blood, 2011

  • Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP)

    Blood, 2011

  • 24-Month Analysis of the Impact of Chelation on Clinical Outcomes in 600 Patient Registry of Lower-Risk MDS Patients

    Blood, 2011

  • Results of Comfort-1, A Randomized, Double-Blind Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib (INCB018424) Versus Placebo for Patients with Myelofibrosis

    16th Congress of the European Hematology Association, 2011

  • Update of an Open-Label Extension Study Evaluating the Long-Term Safety & Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes

    Leukemia Research, 2011

  • A 12-Month Follow-Up of an Ongoing Prospective, Non-Interventional, Multicenter Registry in Iron Overloaded Patients with Lower-Risk Myelodysplastic Syndromes

    Leukemia Research, 2011

  • Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study

    Blood, 2011

  • Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes

    Blood, 2010

  • Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults with Acute Myeloid Leukemia and Unfavorable Prognostic Factors

    Journal of Clinical Oncology, 2010

  • Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma

    Blood, 2010

  • Safety and Efficacy of Romiplostim in Patient with Lower-risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia

    Journal of Clinical Oncology, 2010

  • Improved Quality of Life for Romiplostim-Treated Patients with Chronic Immune Thormbocytopenic Purpura: Results from Two Randomized, Placebo-Controlled Trials

    British Journal of Haematology, 2009

  • Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes

    Journal of Clinical Oncology, 2009

  • Treatment Selection for Myelodysplastic Syndrome Patients in a Community Setting 

    Clinical Advances in Hematology & Oncology, 2009

  • Safety and Efficacy of Long-Term Treatment with Romiplostim in Thrombocytopenic Patients with ITP

    Blood, 2009

  • Clinical Parameters in 391 Iron-Overloaded Patients with Lower-Risk MDS Enrolled in a Prospective, Non-Interventional Multicenter Registry

    Blood, 2009

  • Outpatient Treatment with Clofarabine in Phase II Study of Older Adult Patients with Previously Untreated Acute Myelogenous Leukemia

    Blood, 2009

  • Clorfarabine Produces Durable Remissions in Older Patients with AML with Unfavorable Prognostic Factors and Multiple Comorbidities

    Blood, 2009

  • Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who > or = 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors

    Blood, 2009

  • Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide

    Blood, 2009

  • Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adults with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors

    Blood, 2009

  • An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS)

    Blood, 2009

  • Home Administration of Romiplostim by Patients with Chronic Immune Thrombocytopenia (ITP)

    Blood, 2009

  • Updated Remission Duration and Survival Results of Single-agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia Unlikely to Benefit From Standard Induction Chemotherapy Due to Unfavorable Baseline Risk Factor(s)

    Journal of Clinical Oncology, 2009

  • Results of a Phase II Study of Bortezomib in Patients with Relapsed or refractory Indolent Lymphoma

    Blood, 2008

  • Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab Vs. Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia

    Blood, 2008

  • Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy

    Blood, 2008

  • Self-Injection of Romiplostim by Patients with Chronic Immune Thrombocytopenic Purpura (ITP)

    Blood, 2008

  • Safety and Efficacy of Long-Term Treatment with Romiplostim in Thrombocytopenic Patients with ITP

    Blood, 2008

  • Rapid Onset of Effectiveness with Three Alternative Azacitidine (AZA) Dosing Regimens in Patients with Myelodysplastic Syndromes (MDS)

    Haematologica, 2008

  • Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy

    Journal of Clinical Oncology, 2008

  • Recent Advances in Low- and Intermediate-1--Risk Myelodysplastic Syndrome: Developing a Consensus for Optimal Therapy

    Clinical Advances in Hematology & Oncology, 2008

  • Phase 2, Single-arm, Trial to Evaluate the Effectiveness of Darbopoetin alfa for Correcting Anaemia in Patients with Myelodysplastic Syndromes

    British Journal of Haematology, 2008

  • Efficacy of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura: a Double-blind Randomised Controlled Trial

    Lancet, 2008

  • The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndromes

    Cancer, 2007

  • Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza) in Patients with Myelodysplastic Syndromes (MDS)

    Blood, 2007

  • Evaluation of AMG 531 Safety in Splenectomized (S) and Nonsplenectomized (NS) Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in Two Randomized Placebo-Controlled Phase 3 Studies

    Blood, 2007

  • Health-Related Quality of Life (HRQoL) in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): Results from Two Placebo-Controlled Phase 3 Studies of AMG 531

    Blood, 2007

  • Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients with Low Risk Myelodysplastic Syndrome (MDS): Update on Extended Treatment

    Blood, 2007

  • Thrombocytopenia in MDS: Incidence and Impact

    Supportive Care Cancer, 2007

  • Tolerability and Hematologic Improvement Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes

    Journal of Clinical Oncology, 2007

  • Evaluating Safety and Efficacy of AMG 531 for the Treatment of Thrombocytopenic Patients with Myelodysplastic Syndrome (MDS): Preliminary Results of a Phase 1/2 Study

    Supportive Care Cancer, 2007

  • The Efficacy and Safety of Darbopoetin Alfa For Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Results After 53-55 Weeks

    Journal of Community and Supportive Oncology
    , 2007

  • The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndrome

    Journal of Community and Supportive Oncology, 2007

  • Long-term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-week Update

    Journal of Community and Supportive Oncology
    , 2007

  • Baseline Predictors of Response to Treatment with Darbepoeitin-alpha (DA) in Anemic Patients with Low-risk Myelodysplastic Syndrome (MDS)

    Journal of Clinical Oncology, 2007

  • Evaluating Safety and Efficacy of AMG 531 for the Treatment of Thrombocytopenic Patients with Myelodysplastic Syndrome (MDS): Preliminary Results of a Phase 1/2 Study

    Journal of Clinical Oncology, 2007

  • The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndromes

    Cancer, 2007

  • The Clinical and Direct Medical Cost Burden of Splenectomy Among Managed Care Patients with Chronic Immune Thrombocytopenic Purpura (ITP)

    Blood, 2006

  • Retrospective Matched Cohort Study of Immune Thrombocytopenic Purpura (ITP): Complications Related to Corticosteroid (CS) Use

    Blood, 2006

  • Long-term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenia Purpura: 48-week Update

    Blood, 2006

  • Darbopoetin Alfa for Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Interim Results After 27/28 Weeks

    Journal of Clinical Oncology, 2006

  • The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndromes (MDS)

    Blood, 2006

  • Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes

    Blood, 2006

  • The Efficacy and Safety of Darbopoetin Alfa For Treating Anemia in Low-Risk Myelodysplastic Syndrome Patients: Results After 53-55 Weeks

    Blood, 2006

  • Darbepoetin Alfa for Treating Anemia in Patients with Low-Risk Myelodysplastic Syndromes: Exploratory Analysis of Baseline Predictors of Response

    Journal of Clinical Oncology, 2006

  • Transfusion Independence Assessed During Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes

    Journal of Clinical Oncology, 2006

  • AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP

    New England Journal of Medicine, 2006

  • Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period

    Clinical and Applied Thrombosis/Hemostasis, 2006